Autopsy report · NCT04387071
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
Cause of deathDrug or device supply
“Study drug no longer available”
Life of this trial
- Registered 1 year before it started.
- Ran for about 1 year 8 months before it stopped.
- 2 participants enrolled.
- Results were posted on the registry 3 years 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Conditions
- Locally Advanced Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8; Unresectable Malignant Solid Neoplasm
- Interventions
- Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949; VLP-encapsulated TLR9 Agonist CMP-001
- Participants
- 2
- Sites
- 4
- Countries
- United States
Trials that died the same way
- Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
“study drug unavailable” - An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants
“Study medication was no longer available for study” - TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
“Drug no longer available” - P1101 in Treating Patients With Myelofibrosis
“Study drug became commercially available” - Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
“Drug was no longer available”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.